- Inmode’s preliminary first-quarter revenue is between $77.2 million and $77.5 million.
- This revenue figure is below the estimated $82.2 million.
- The company maintains its full-year revenue forecast of $395 million to $405 million.
- The forecast remains slightly above the market estimate of $394.5 million.
- Inmode anticipates an adjusted gross margin of 78% to 79% for the first quarter.
- Despite missing revenue estimates, Inmode’s shares increased by 2.1% in pre-market trading.
- The stock is priced at $15.19 with 2,322 shares traded.
- Analyst recommendations include 3 buys, 4 holds, and 0 sells.
A look at Inmode Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Inmode’s long-term outlook appears promising. With a solid score in resilience, indicating the company’s ability to weather economic uncertainties, Inmode is positioned to withstand market fluctuations. Additionally, its respectable scores in value, growth, and momentum suggest room for further development and positive performance in the coming years. However, the low dividend score signifies a lack of dividend payouts for investors seeking regular income streams.
InMode Ltd., a company that specializes in developing medical devices utilizing radio-frequency technology, has demonstrated a strong global presence, catering to a wide range of customers. With a focus on innovation and efficiency, Inmode’s diversified product platforms are designed to benefit both patients and practitioners. The combination of these factors, along with its favorable scores across various categories, indicates a promising trajectory for Inmode’s growth and market position in the long run.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
